Papular perniosis mimicking erythema multiforme: the first case report in Thailand.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to N Noppakun.
Explore the source record for details and available documents.
Thirty patients with the clinical and laboratory proven diagnosis of either tinea corporis or tinea cruris were treated with a new systemic antifungal agent, itraconazole. Itraconazole, a triazole derivative, interacts specifically with fungal cytochrome P-450 and has high affinity for skin and mucous membrane. In this open non-comparative clinical trial, itraconazole was given orally in the dosage of 100 mg per day for 14 consecutive days. Twenty-nine cases (96.6%) had good clinical response with 83.3 per cent mycological cure rate. Complete healing of cutaneous lesions was 56.6 per cent at the end of therapy (14 days) and increased to 83.3 per cent two weeks later. No significant side effects were noted. Itraconazole is highly effective in treatment of dermatophytosis with a shorter treatment period than other conventional antifungal agents.
Twenty-three patients were enrolled in a randomized, double-blind trial of terbinafine 1% cream compared with placebo vehicle in the treatment of tinea pedis. Of the 20 patients who were evaluated for efficacy, 10 received terbinafine and 10 received placebo. Except for the terbinafine-treated patients being an average of 11 years older than the patients receiving placebo and the median duration of disease being 6 weeks longer in the placebo group, the two groups were demographically and clinically similar. Results of mycologic tests and clinical findings showed terbinafine to be significantly more effective than placebo in the treatment of tinea pedis. Significantly more terbinafine-treated patients than placebo-treated patients showed conversion to negative culture and microscopy at end of therapy and a significant reduction in scored signs and symptoms. Overall efficacy at follow-up (combined mycologic and clinical findings) was also significantly greater in the terbinafine group (78%) than in the placebo group (zero) (p less than 0.001). Unexplained elevation of liver function test results was noted in three placebo-treated patients and in one terbinafine-treated patient, but these changes were not considered clinically relevant or drug related.
Explore the source record for details and available documents.
An urticarial dermatosis after contact with the urticating hairs of the adult female Hylesia moth may occur by several mechanisms including the intradermal injection of inflammatory mediators through the urticating hairs. Extracts were prepared from whole moths, urticating hairs, and other moth parts. Each of these extracts was subjected to a radioenzyme assay for histamine. Histamine was present in extracts made from whole moths and from urticating hairs. Extracts made from other moth parts contained no histamine. Cutaneous wheals occurred after intradermal injections of histamine and various concentrations of Hylesia extract (HE) into the backs of cynomolgus monkeys. This whealing response was suppressed by pretreatment of the animals with diphenhydramine hydrochloride, but not by pretreatment with indomethacin. Histologic examinations showed a perivascular lymphocytic infiltrate around dilated capillaries without evidence of mast cell degranulation in HE-injected sites but not in controls. These findings provide evidence that histamine may be the mediator responsible for the urticarial lesions seen after contact with Hylesia moths.
Sterile, pruritic papules and papulopustules that formed annular rings developed on the back of a 58-year-old woman. The individual lesions evidenced peripheral extension with central clearing and were characterized by exacerbations and partial remissions. The general health of the patient was good. Laboratory determinations showed moderate peripheral blood eosinophilia. Spongiosis with eosinophilic exocytosis, often localized to the hair follicles, was found on examination of histologic specimens. These findings led to a diagnosis of eosinophilic pustular folliculitis, a disease of unknown cause that has rarely been reported in the North American literature.
Explore the source record for details and available documents.
A 5-month-old male was examined in our dermatology clinic with numerous palmoplantar milia. The child had early congenital syphilis with palmoplantar desquamation, which was followed by the development of milia. Histologic and electron microscopic features suggested that these secondary milia probably derived from the epidermis.
A case of reversible generalized hyperpigmentation of the skin and nails with reversible premature gray hair due to vitamin B12 deficiency is reported. The cause of the vitamin B12 deficiency in this patient was pernicious anemia. The pigmentation of his skin and hair returned to normal after treatment with intramuscular cyanocobalamin.
Three patients with Graves' disease had very unusual locations of localized myxedema. One patient had localized myxedema on the pretibial and shoulder areas after sodium iodide I 131 therapy. The second patient had localized myxedema on his neck, shoulders, and upper part of the back as well as on the pretibial area. The third patient had localized myxedema on the pinnae, also following sodium iodide I 131 therapy. After surgical removal followed by intralesional triamcinolone acetonide injections, the first patient's lesions recurred. The lesions in the second case did not respond to topical steroid cream. The third patient had a partial response to intralesional steroid injections.
A 37-year-old black man with 64 pruritic cutaneous granular cell tumors represents the highest number of such lesions ever reported. The clinical resemblance to prurigo nodularis are the unique features. Partial response to intralesional corticosteroid injection is noted.